Trial Profile
A Phase I/II Study of MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Ixazomib (Primary) ; Dexamethasone; Panobinostat
- Indications Multiple myeloma
- Focus Adverse reactions
- 10 Dec 2019 Status changed from active, no longer recruiting to completed.
- 07 May 2019 Planned End Date changed from 1 Dec 2018 to 15 May 2019.
- 20 Mar 2018 Planned End Date changed from 1 Jan 2018 to 1 Dec 2018.